Novavax (NASDAQ:NVAX) Stock, Quote.Headers.trade-ideas

Novavax

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.

Updated Vaccines In The Fall

Biotech

Government

News

Health Care

Legal

Media

General

BNTX

MRNA

NVAX

Florida advises against mRNA Covid vaccines for vulnerable residents, citing safety concerns. Gov. DeSantis&#39; administration urges healthcare providers to prioritize alternative vaccines for seniors and high-risk individuals.

DeSantis Administration Cautions Against Pfizer, Moderna mRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions

Istanbul,,Tr,-,January,29,2021:,Novavax,Vaccine.,Syringe,Close

Movers

Novavax Inc. (NASDAQ: NVAX) shares are trading lower Thursday following multiple significant announcements. Here&#39;s what you need to know.

Why Are Novavax Shares Trading Lower Today?

Stock_Whisper_Index_Logo_6-copy

REIT

Stock Split

Exclusives

Tech

Trading Ideas

Real Estate

EQIX

ORCL

TNON

WHLR

Here&#39;s a look at five stocks that saw increased attention from Benzinga readers during the week and the reasons why.

Benzinga&#39;s &#39;Stock Whisper&#39; Index: 5 Stocks Investors Secretly Monitor But Don&#39;t Talk About Yet

Novavax Inc

Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) has outperformed the market over the past 5 years by 1.97% on an annualized basis producing an average annual return of 15.62%. Currently, Novavax has a market capitalization of $2.14 billion. 
Buying $1000 In NVAX: If an investor had bought $1000 of NVAX stock 5 years ago, it would be worth $2,000.00 today based on a price of $13.38 for NVAX at the time of writing.
<h3>Novavax's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726581683_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Novavax 5 Years Ago Would Be Worth This Much Today

Florida Governor Ron DeSantis' administration has reportedly issued updated guidance recommending that healthcare providers steer vulnerable patients away from mRNA-based COVID-19 vaccines.
The Florida Health Department is raising concerns about the safety of the mRNA vaccines, pointing to potential risks such as myocarditis and postural orthostatic tachycardia syndrome (POTS), rare heart conditions. This stance contrasts sharply with recommendations from federal health agencies, which continue to endorse mRNA vaccines as safe and effective for all eligible individuals.
In June, the U.S. CDC recommended <a target="_blank" href="https://www.cdc.gov/media/releases/2024/s-t0627-vaccine-recommendations.html" rel="noreferrer noopener">using</a> updated 2024-2025 COVID-19 vaccines in individuals six months and older.
The FDA in August <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40514864/fda-approves-updated-covid-vaccines-from-pfizer-and-moderna-but-leaves-out-novavaxs-shot" rel="noreferrer noopener">granted emergency use</a> approval for updated mRNA-based COVID-19 vaccines from Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) and Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)/BioNTech SE's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>), targeting the Omicron variant KP.2 strain.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40347291/long-covid-remains-diagnostic-mystery-diagnosis-remains-elusive-national-institutes-of-health-fun" rel="noreferrer noopener">Long Covid Remains Diagnostic Mystery, Diagnosis Remains Elusive; National Institutes of Health-Funded Study Shows</a>.
The NBC News highlights that the state's health department is advising that individuals aged 65 and older, along with those with underlying health conditions, prioritize access to non-mRNA vaccines and treatments instead.
Earlier this month, the FDA granted Emergency Use Authorization to&nbsp;Novavax Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>)&nbsp;protein-based COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) for active immunization to prevent COVID-19 in&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/n40660946/novavax-2024-2025-formula-covid-19-vaccine-now-authorized-and-recommended-for-use-in-the-u-s" rel="noreferrer noopener">individuals aged 12 and older</a>.
The state's guidance emphasizes that high immunity levels from prior infections, combined with current data, justify their position.
The report <a target="_blank" href="https://www.nbcnews.com/health/health-news/florida-covid-shots-mrna-vaccines-older-adults-rcna170997" rel="noreferrer noopener">adds</a> that while there is a documented small risk of myocarditis linked to the mRNA vaccines, especially in younger males, studies show most cases are mild and resolve fully.
Research published in Nature Cardiovascular Research highlights that individuals infected with COVID-19 are five times more likely to develop POTS than those vaccinated with mRNA vaccines, reinforcing the importance of vaccination.
Researchers from the Universities of Cambridge, Bristol, and Edinburgh revealed that COVID-19 vaccinations may significantly reduce the incidence of arterial thromboses, a leading cause of <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40348867/struggling-covid-19-vaccines-from-astrazeneca-biontechpfizer-moderna-cut-incidence-of-arterial-th" rel="noreferrer noopener">heart attacks and strokes</a>.
Price Action: MRNA stock is up 2.37% to $69.90, PFE stock is up 2.12% to $29.89 at the last check on Monday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40875211/bhp-group-sounds-alarm-on-copper-supply-ai-and-ev-growth-could-drive-prices-soaring-report" target="_blank" rel="noreferrer noopener">BHP Group Sounds Alarm on Copper Supply, AI and EV Growth Could Drive Prices Soaring: Report</a>.</li>
</ul>
Image via Shutterstock

<a href="https://www.nbcnews.com/health/health-news/florida-covid-shots-mrna-vaccines-older-adults-rcna170997">https://www.nbcnews.com/health/health-news/florida-covid-shots-mrna-vaccines-older-adults-rcna170997</a>
Even as the Covid wave in Florida continues, Gov. Ron DeSantis' administration is once again advising against the mRNA vaccines: this time in the most vulnerable residents.
In updated guidance for health care providers released Thursday, the Florida Health Department and state Surgeon General Joseph Ladapo questioned the safety and effectiveness of <a href="https://content.govdelivery.com/accounts/FLDOH/bulletins/3b56786">the mRNA Covid vaccines</a> from Pfizer and Moderna, including for older adults and people with underlying health problems. "Any provider concerned about the health risks associated with Covid-19 for patients over the age of 65 or with underlying health conditions should prioritize patient access to non-mRNA Covid-19 vaccines and treatment," according to the state guidance.
Standing in opposition to <a href="https://www.nbcnews.com/health/health-news/new-covid-vaccine-what-know-when-available-timing-rcna167121">advice from federal health agencies</a> and other medical experts about the safety of the Covid vaccines,&nbsp;the Florida Health Department said the recommendation was based on high rates of immunity from prior infections and "currently available data."
Without noting the <a href="https://www.cdc.gov/covid/risk-factors/index.html#:~:text=Older%20adults%20are%20at%20highest,people%20ages%2018%2D29%20years.">high risk of serious Covid infection or hospitalization for older adults</a>, the guidance listed safety concerns for the mRNA vaccines, including the risk of a rare heart condition called myocarditis, as well as the risk of <a href="https://www.nbcnews.com/health/health-news/pots-debilitating-heart-condition-linked-covid-lesser-degree-vaccines-rcna61226">POTS, or postural orthostatic tachycardia syndrome</a>, a debilitating heart condition.&nbsp;
Numerous studies have shown that both Pfizer and Moderna's vaccines are indeed associated with a small <a href="https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html">but increased risk of myocarditis</a>. However, most cases occur in young men and most people make a full recovery. Studies have also shown that the risk of myocarditis is much higher with a Covid infection and is often more severe than the vaccine-associated condition.
A study published <a href="https://www.nature.com/articles/s44161-022-00177-8">in Nature Cardiovascular Research</a>​ also found that people diagnosed with Covid are five times more likely to develop POTS after infection than after Covid vaccination, emphasizing the importance of the vaccine.
Dr. Paul Offit, a vaccine expert at Children's Hospital of Philadelphia, said the Florida surgeon general's guidance is unnecessarily alarming people about the Covid vaccines.
"It's just such a dangerous game he plays," said Offit, who has served on the FDA's independent vaccine advisory committee. "You only have a roughly 1,000 times greater likelihood of dying [from Covid] if you're over 65 than if you're under 18."
"The mRNA vaccines are remarkably safe," he added.
New doses of the Pfizer and Moderna vaccines were <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-and-authorizes-updated-mrna-covid-19-vaccines-better-protect-against-currently">approved by the Food and Drug Administration</a> in August. They're targeted to the <a href="https://publichealth.jhu.edu/2024/what-to-know-about-covid-flirt-variants">KP.2 version of the steadily mutating virus </a>and should provide good protection against severe illness, hospitalization and death, experts say.&nbsp;
&nbsp;
The United States offers only one <a href="https://www.nbcnews.com/health/health-news/fda-authorizes-novavaxs-updated-covid-vaccine-targeting-jn1-strain-rcna169065">Covid vaccine that isn't mRNA-based: Novavax.</a> Novavax's traditional protein-based shot offers an alternative vaccine technology to mRNA. &nbsp;
In a statement, a Novavax spokesperson said its updated vaccine is now available at thousands of retail and pharmacy locations nationwide.
The Florida Health Department did not immediately respond to a request for additional comment.&nbsp;
Dr. Isaac Bogoch, an infectious disease specialist at the University of Toronto, called Florida's recommendation "unfortunate," saying it could put older adults and people with underlying health conditions at risk.
"While the vaccine does not protect against infection nearly as well as it once did, there is very good data demonstrating how Covid vaccines can reduce the risk of severe manifestations of the virus in those who are at greatest risk," said Boguch, who has no ties to the vaccine makers.&nbsp;
Covid cases remain high in the U.S. following a summer wave. Wastewater data collected between Aug. 25 and Aug. 31 shows that 23 states -- including Florida -- are reporting "very high" levels of the virus, <a href="https://www.cdc.gov/nwss/rv/COVID19-currentlevels.html">according to the CDC</a>. Emergency department visits and hospitalizations remain <a href="https://covid.cdc.gov/covid-data-tracker/#datatracker-home">elevated as well</a>, although they're showing signs of declining. In Florida nursing homes, after declining from summer highs, Covid infections are ticking up again, <a href="https://www.cdc.gov/nhsn/covid19/ltc-report-overview.html#anchor_1594393304">according to CDC data.&nbsp;</a>
&nbsp;
The CDC <a href="https://www.cdc.gov/media/releases/2024/s-t0627-vaccine-recommendations.html">currently recommends</a> everyone ages 6 months and older get an updated Covid vaccine this fall from any of the three options.&nbsp;
This isn't the first time Ladapo has ignored CDC guidance. Last year, Ladapo <a href="https://www.nbcnews.com/health/health-news/desantis-administration-advises-no-covid-shots-under-65-rcna104912">also recommended</a> that Florida residents under the age of 65 not get the mRNA Covid vaccines, citing widespread immunity and "questions we have about safety and about effectiveness."
"My judgment is that it's not a good decision for young people and for people who are not at high risk at this point in the pandemic," he said.&nbsp;

"Florida Discourages Use Of mRNA Covid Vaccines In Older Adults; In Updated Guidance To Health Care Providers, Florida Health Officials Advise That "Non-mRNA Covid-19 Vaccines And Treatment" Should Be Prioritized" - NBC News

WIIM

Novavax shares are trading higher after the company announced doses of its 2024-2025 Formula COVID-19 vaccine are now available at thousands of locations nationwide.

<ul>
<li>Doses of Novavax's 2024-2025 Formula COVID-19 vaccine now available at thousands of locations nationwide</li>
<li>Novavax's updated vaccine is the only protein-based option available in the U.S. this fall for individuals aged 12 and older</li>
</ul>

Does Of Novavax 2024-2025 Formula COVID-19 Vaccine Available Across U.S.

Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) shares are on watch Thursday. Here&#8217;s a recap of recent events. 
Key Developments:
<ul>
<li>Short Interest: Novavax's short interest has fallen, signaling that fewer investors are betting against the stock. It would take about 3.09 days to cover all short positions based on average trading volumes.</li>
<li>FDA Approval: Novavax's updated COVID-19 vaccine has been approved and will be available at thousands of locations across the U.S., including retail pharmacies and grocers. This approval strengthens Novavax's position in the market as it continues to offer a unique protein-based vaccine alternative.</li>
<li>Revenue Guidance: In August, Novavax lowered its 2024 revenue guidance to between $700 million and $800 million, significantly below earlier projections.</li>
</ul>
In comparison, Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) also shared updates during its R&amp;D day, projecting 2025 revenues of $2.5 billion to $3.5 billion, below the consensus of $3.74 billion. The company is cutting its R&amp;D budget by $1.1 billion by 2027 and focusing on ten prioritized products. Despite lower-than-expected revenue forecasts, Moderna remains confident in its long-term growth and cash reserves.
NVAX Price Action: Novavax shares were down by 2.48% at $11.99 according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1722883001180099"><img loading="lazy" decoding="async" width="1024" height="550" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12104437/NVAX-1024x550.png" alt="" class="wp-image-544971" style="width:514px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12104437/NVAX-1024x550.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12104437/NVAX-300x161.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12104437/NVAX-768x413.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12104437/NVAX.png 1074w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/technicals/24/09/40835602/jim-cramer-sees-opportunity-in-micron-stock-as-death-cross-earnings-approach">Jim Cramer Sees Opportunity In Micron Stock As Death Cross, Earnings Approach</a></li>
</ul>
Photo via Shutterstock.

Novavax shares are trading lower. The stock may be down in sympathy with vaccine maker Moderna, which cut its R&D outlook.

Each week,&nbsp;Benzinga's Stock Whisper Index&nbsp;uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the&nbsp;<a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">surface and deserve attention</a>.
Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance of information to uncover new opportunities and understand why certain stocks should be of interest.
Here&#8217;s a look at the Benzinga Stock Whisper Index for the week of Sept. 6:
Oracle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>): The technology giant is seeing strong interest from Benzinga readers ahead of Monday's first-quarter financial results. 
The company is expected to report earnings per share of $1.33, up from $1.19 in last year's first quarter, according to data<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090624&amp;t=be2bearmibe3na1"> from Benzinga Pro.</a> The company has beaten earnings per share estimates from analysts in seven straight quarters and eight of the past 10 quarters overall. 
Analysts estimate the company will report first-quarter revenue of $13.24 billion, up from $12.94 billion in last year's first quarter. The company has missed revenue estimates from analysts in four straight quarters and six of the past 10 quarters overall. 
Oracle <a href="https://www.benzinga.com/news/earnings/24/06/39280057/oracle-misses-q4-earnings-stock-surges-on-booming-ai-demand-openai-contract-partnership-with-google">highlighted AI demand</a> in the fourth quarter with more than 30 AI sales contracts valued at over $12.5 billion signed, including a large contract with OpenAI. Oracle also announced a partnership with Google Cloud at the time.
Oracle shares are up 2.3% over the last five days, as seen on the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090624&amp;t=be2bearmibe3na1">Benzinga Pro chart </a>below. Oracle stock is up 38% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="993" height="502" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105358/Screenshot-162.png" alt="" class="wp-image-534842" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105358/Screenshot-162.png 993w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105358/Screenshot-162-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105358/Screenshot-162-768x388.png 768w" sizes="(max-width: 993px) 100vw, 993px" /></a></figure>
Novavax Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>): Shares of the vaccine company were up over 4% in the past five days with news that the FDA granted Emergency Use Authorization of the company's<a href="https://www.benzinga.com/general/biotech/24/09/40688052/fda-approves-novavaxs-updated-covid-vaccine-targeting-currently-circulating-variants"> updated COVID-19 vaccine</a>. The updated vaccine is included in the recommendations from the U.S. Centers for Disease Control and Prevention (CDC). 
The vaccine is the only protein-based option available in the U.S. for people aged 12 and older for the prevention of COVID-19. The company could also be drawing interest from investors ahead of two company presentations next week. Novavax will present at H.C. Wainwright and Baird investor conferences on Monday, Sept. 9 and Tuesday, Sept. 10, respectively.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="989" height="502" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105414/Screenshot-163.png" alt="" class="wp-image-534844" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105414/Screenshot-163.png 989w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105414/Screenshot-163-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105414/Screenshot-163-768x390.png 768w" sizes="(max-width: 989px) 100vw, 989px" /></a></figure>
Read Also: <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40691773/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-august-2024-where-do-tesla-n">EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In August 2024 – Where Do Tesla, Nvidia, Apple, AMD Stock Rank?</a>
Wheeler Real Estate Investment Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>): Shares of the real estate investment trust surged over 500% on the week after the company <a href="https://ir.whlr.us/news-events/press-releases/detail/1088/cedar-realty-trust-and-wheeler-real-estate-investment-trust-announce-fourth-circuit-court-affirms-dismissal-of-class-action-lawsuit">announced </a>a circuit court affirmed the dismissal of a class action lawsuit involving holders of Cedar Realty preferred stock. Wheeler acquired Cedar in August 2022 and the lawsuit alleged a breach of contract related to Cedar's former board of directors.
"With this matter behind us, both companies remain well-positioned to execute on their strategic plans," Cedar and Wheeler CEO Andrew Franklin said.
The company owns 77 grocery-anchored shopping centers in the Northeast, Mid-Atlantic and Southeast covering 14 states. With the lawsuit behind the company, investors could see a positive long-term outlook.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="997" height="504" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105430/Screenshot-164.png" alt="" class="wp-image-534845" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105430/Screenshot-164.png 997w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105430/Screenshot-164-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105430/Screenshot-164-768x388.png 768w" sizes="(max-width: 997px) 100vw, 997px" /></a></figure>
Equinix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>): The data center company saw strong interest from investors on the week with shares up minimally. The company <a href="https://investor.equinix.com/news-events/press-releases/detail/1051/equinix-issues-more-than-750-million-in-green-bonds-to">announced </a>it issued $750 million in green bonds across two completed offerings. The green bonds are being used to help with sustainability initiatives for the company.
"Green bonds serve as a valuable means to secure funding and support significant initiatives that enhance the sustainability of our operations," Equinix SVP Corporate Finance and Sustainability Katrina Rymill said. "Over the last five years, our green bonds have funded 172 green building projects across 105 sites, 33 energy efficient projects and two Power Purchase Agreement projects."
The new green bonds could help the company continue to invest in new efforts to help support the company's 86 consecutive quarters of top-line revenue growth, which the company said is the longest streak of any S&amp;P 500 company.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="995" height="502" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105452/Screenshot-165.png" alt="" class="wp-image-534850" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105452/Screenshot-165.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105452/Screenshot-165-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105452/Screenshot-165-768x387.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
Tenon Medical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>): Investor interest in the medical device company grew during the week thanks to two <a href="https://ir.tenonmed.com/">items</a>. The company announced a 1:8 reverse stock split on Sept. 4 that took effect on Sept. 6. Reverse stock splits often draw attention from retail investors as they reduce the float and shares outstanding of a company. 
Tenon also announced a peer-reviewed publication of its Catamaran SI Joint Fusion System. The peer review showed evidence of fusion at the 12-month mark post-procedure, the company said.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="991" height="502" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105510/Screenshot-166.png" alt="" class="wp-image-534851" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105510/Screenshot-166.png 991w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105510/Screenshot-166-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105510/Screenshot-166-768x389.png 768w" sizes="(max-width: 991px) 100vw, 991px" /></a></figure>
Stay tuned for next week's report, and follow Benzinga Pro for all the latest headlines and&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090624&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">top market-moving stories here.</a>
Read the latest Stock Whisper Index reports here:
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/08/40284758/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">August 9</a></li>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40420145/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">August 16</a></li>
<li><a href="https://www.benzinga.com/top-stories/24/08/40531771/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">August 23</a></li>
<li><a href="https://www.benzinga.com/exclusives/24/08/40653930/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">August 30</a></li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40748240/how-to-earn-500-a-month-from-oracle-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Oracle Stock Ahead Of Q1 Earnings</a></li>
</ul>

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Novavax's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NYSE">NVAX</a>) short percent of float has fallen 17.52% since its last report. The company recently reported that it has 28.76 million shares sold short, which is 22.41% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.09 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Novavax Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725458423_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Novavax has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Novavax's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Novavax's peer group average for short interest as a percentage of float is 11.76%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Novavax?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) dipped 11.6% to $6.43. The company on Tuesday announced Phase 2 data for an investigational treatment for symptomatic Cerebral Cavernous Malformation (CCM).
Nikola shares dipped 10.4% to $7.28 on Monday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Sify Technologies Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIFY#NASDAQ">SIFY</a>) shares jumped 103% to $0.6719. Sify becomes first in India to achieve NVIDIA DGX-ready data center certification for liquid cooling to enable breakthrough AI performance.</li>
<li>BranchOut Food Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOF#NASDAQ">BOF</a>) gained 85% to $3.70.</li>
<li>SPAR Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGRP#NASDAQ">SGRP</a>) surged 65% to $2.3950 after the company announced it entered into a definitive agreement to be acquired by Highwire Capital for $2.50 per share.</li>
<li>Asset Entities Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASST#NASDAQ">ASST</a>) rose 62.7% to $2.31.</li>
<li>Conifer Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNFR#NASDAQ">CNFR</a>) shares jumped 56% to $1.0250 after the company announced that it completed the sale of its insurance agency operations for a $45 million consideration. The company appointed Brian Roney as CEO.</li>
<li>Auddia Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUUD#NASDAQ">AUUD</a>) gained 44.6% to $1.25 after the company announced it recently launched both Apple CarPlay and Android Auto interfaces for its faidr mobile application.</li>
<li>Vaxcyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCVX#NASDAQ">PCVX</a>) surged 43.5% to $115.92 after the company announced it selected VAX-31 to advance to an adult Phase 3 program following topline results from its Phase 1/2 study.</li>
<li>Sable Offshore Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOC#NYSE">SOC</a>) gained 28.8% to $21.69.</li>
<li>Shoals Technologies Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) rose 21.8% to $6.57 after the company received a favorable legal ruling from the U.S. ITC in its patent infringement complaint against Voltage, LLC and a related foreign entity.</li>
<li>TC Biopharm (Holdings) Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) jumped 17.5% to $6.55 after the company announced it dosed 5 new patients in its ACHIEVE Phase 2b trial.</li>
<li>AGM Group Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGMH#NASDAQ">AGMH</a>) rose 16.5% to $1.27.</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) gained 16% to $1.4150 after the company appointed former Stellantis executive Jean-Francois Mady as its new CFO.</li>
<li>Chemomab Therapeutics Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMMB#NASDAQ">CMMB</a>) surged 15.8% to $2.34.</li>
<li>MediciNova, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) gained 15.3% to $1.73. MediciNova recently announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application, which covers MN-166 for post-COVID conditions.</li>
<li>GD Culture Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDC#NASDAQ">GDC</a>) rose 12.8% to $6.86.</li>
<li>Big Tree Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSY#NASDAQ">DSY</a>) jumped 12.6% to $5.99.</li>
<li>Avalo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>) gained 11.4% to $8.29.</li>
<li>Motorsport Games Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSGM#NASDAQ">MSGM</a>) rose 11.3% to $1.3250.</li>
<li>Applied Optoelectronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) gained 10.7% to $12.57 after Raymond James upgraded the stock from Market Perform to Outperform and announced a $17 price target.</li>
<li>Unity Software Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) gained 9.4% to $17.91 after Morgan Stanley upgraded the stock from Equal-Weight to Overweight.</li>
<li>Intchains Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICG#NASDAQ">ICG</a>) climbed 8.1% to $7.89.</li>
<li>Keros Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>) gained 8.1% to $49.04 after the company announced an update on enrollment in the Phase 2 TROPOS trial.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) gained 4.5% to $12.94. Friday, the FDA granted Emergency Use Authorization to Novavax Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) for active immunization to prevent COVID-19 in individuals aged 12 and older.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Windtree Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares dipped 42.2% to $4.68.</li>
<li>Dyne Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) fell 31.7% to $31.47. The company announced new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts.</li>
<li>Agape ATP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) shares fell 31.3% to $1.75 after jumping 60% on Friday.</li>
<li>IO Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) dipped 29.3% to $1.06 after the company announced the IDMC observed no new safety signals in the Phase 3 trial of IO102-IO103. Also, Morgan Stanley maintained an Overweight rating on the stock but lowered its price target from $7 to $4.</li>
<li>Brenmiller Energy Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNRG#NASDAQ">BNRG</a>) fell 25.8% to $1.1499. Brenmiller recently reported a year-over-year increase in H1 EPS results. Also, the company announced a projected pipeline valued up to $500 million.</li>
<li>Silexion Therapeutics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) dipped 22.8% to $1.13.</li>
<li>Four Seasons Education (Cayman) Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FEDU#NYSE">FEDU</a>) fell 21.8% to $13.30.</li>
<li>Quantum BioPharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#NASDAQ">QNTM</a>) declined 21.6% to $3.55.</li>
<li>Applied DNA Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) fell 18.8% to $1.5506.</li>
<li>Xiao-I Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIXI#NASDAQ">AIXI</a>) dipped 18.6% to $3.99.</li>
<li>NANO Nuclear Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) fell 16.1% to $8.49.</li>
<li>LightInTheBox Holding Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITB#NASDAQ">LITB</a>) declined 14.3% to $0.4455.</li>
<li>NovoCure Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>) fell 12.7% to $16.97 as the company announced planned CEO transition.</li>
<li>Geron Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) fell 10.8% to $4.2350.</li>
<li>Nova Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVMI#NASDAQ">NVMI</a>) declined 9.6% to $202.16.</li>
<li>Tidewater Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDW#NYSE">TDW</a>) fell 8.5% to $81.15.</li>
<li>Sterling Infrastructure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRL#NASDAQ">STRL</a>) fell 8.5% to $109.35.</li>
<li>The Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) fell 8.3% to $159.27 ahead of the September 12 expiration of the company&#8217;s contract with the International Association of Machinists, which could lead to a potential strike. Additionally, Wells Fargo downgraded the stock from Equal-Weight to Underweight.</li>
<li>Avis Budget Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>) dipped 8% to $75.43.</li>
<li>Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) fell 7.2% to $70.73.</li>
<li>Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) declined 7% to $20.52.</li>
<li>Applied Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) fell 6.2% to $185.01.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/40683473/top-3-tech-and-telecom-stocks-which-could-rescue-your-portfolio-this-month">Top 3 Tech And Telecom Stocks Which Could Rescue Your Portfolio This Month</a></li>
</ul>

Intraday Update

Markets

AAOI

AGMH

AIXI

AMAT

APDN

ASST

ATPC

AUUD

AVTX

BNRG

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

CNFR

FEDU

GERN

INTC

IOBT

KROS

LITB

MNOV

MRVL

MSGM

NVCR

NVMI

PCVX

PSNY

QNTM

RXRX

SGRP

SHLS

SIFY

SLXN

STRL

TCBP

WINT

Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

U.S. stocks were lower, with the Nasdaq Composite falling around 2% on Tuesday.
Shares of Vaxcyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCVX#NASDAQ">PCVX</a>) rose sharply during Tuesday's session after the company released topline results from the Phase 1/2 study evaluating the safety, tolerability and immunogenicity of VAX-31, the company&#8217;s 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent <a href="https://www.benzinga.com/general/biotech/24/09/40688264/bacterial-infections-vaccine-developer-vaxcytes-pneumococcal-shot-shows-promise-in-mid-stage-tria">invasive pneumococcal disease.</a>
VAX-31 was well tolerated and demonstrated a safety profile at all doses studied through the full six-month evaluation period, similar to Pfizer Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Prevnar 20 (PCV20).
Vaxcyte shares jumped 43.5% to $115.92 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Sable Offshore Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOC#NYSE">SOC</a>) shares rose 28.8% to $21.69.</li>
<li>Shoals Technologies Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) gained 21.8% to $6.57 after the company received a favorable legal ruling from the U.S. ITC in its patent infringement complaint against Voltage, LLC and a related foreign entity.</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) rose 16% to $1.4150 after the company appointed former Stellantis executive Jean-Francois Mady as its new CFO.</li>
<li>Big Tree Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSY#NASDAQ">DSY</a>) gained 12.6% to $5.99.</li>
<li>Applied Optoelectronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) jumped 10.7% to $12.57 after Raymond James upgraded the stock from Market Perform to Outperform and announced a $17 price target.</li>
<li>Unity Software Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) rose 9.4% to $17.91 after Morgan Stanley upgraded the stock from Equal-Weight to Overweight.</li>
<li>BridgeBio Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>) jumped 8.5% to $30.24. HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterated BridgeBio Pharma with a Buy and maintained a $43 price target.</li>
<li>Montana Technologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRJ#NASDAQ">AIRJ</a>) gained 8.4% to $6.05.</li>
<li>Intchains Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICG#NASDAQ">ICG</a>) gained 8.1% to $7.89.</li>
<li>Keros Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>) climbed 8.1% to $49.04 after the company announced an update on enrollment in the Phase 2 TROPOS trial.</li>
<li>XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) rose 4.8% to $8.44. XPeng delivered 14K smart EVs in August, up by 3% year over year.</li>
<li>Vera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) gained 4.5% to $39.53. JP Morgan analyst Anupam Rama maintained Vera Therapeutics with an Overweight and raised the price target from $62 to $72.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) rose 4.5% to $12.94. Friday, the FDA granted Emergency Use Authorization to the company's COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) for active immunization to prevent COVID-19 in individuals aged 12 and older.</li>
<li>Bilibili Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>) gained 3.7% to $14.91. B of A Securities analyst Brad Sills maintained Bilibili with a Buy and raised the price target from $18 to $19.</li>
<li>The J. M. Smucker Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SJM#NYSE">SJM</a>) rose 3.1% to $118.27.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/40683473/top-3-tech-and-telecom-stocks-which-could-rescue-your-portfolio-this-month"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/40683473/top-3-tech-and-telecom-stocks-which-could-rescue-your-portfolio-this-month">Top 3 Tech And Telecom Stocks Which Could Rescue Your Portfolio This Month</a></li>
</ul>

AIRJ

BBIO

BILI

VERA

XPEV

Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday

Friday, the FDA granted Emergency Use Authorization to Novavax Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) for active immunization to prevent COVID-19 in&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/n40660946/novavax-2024-2025-formula-covid-19-vaccine-now-authorized-and-recommended-for-use-in-the-u-s" rel="noreferrer noopener">individuals aged 12 and older</a>.
Novavax&#8217;s vaccine is included in the recommendations issued by the U.S. Centers for Disease Control and Prevention (CDC) on&nbsp;June 27, 2024.
Following the Center for Biologics Evaluation and Research&#8217;s release of vaccine batches, pre-filled syringes of the vaccine will be available in thousands of locations, including retail and independent pharmacies and regional grocers.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40514864/fda-approves-updated-covid-vaccines-from-pfizer-and-moderna-but-leaves-out-novavaxs-shot" rel="noreferrer noopener">FDA Approves Updated COVID Vaccines From Pfizer And Moderna, But Leaves Out Novavax&#8217;s Shot</a>.
&#8220;Our updated vaccine targets JN.1, the &#8216;parent strain&#8217; of currently circulating variants, and has shown robust cross-reactivity against JN.1 lineage viruses, including KP.2.3, KP.3, KP.3.1.1 and LB.1,&#8221; said John C. Jacobs, President and Chief Executive Officer, Novavax.
In June, the CDC&#8217;s Advisory Committee on Immunization Practices voted unanimously in favor of a universal recommendation for the use of 2024-2025 COVID-19 vaccines authorized under EUA or approved by Biologics License Application in individuals aged six months and older, regardless of specific viral strains.
The approval was based on non-clinical data that showed Novavax&#8217;s updated vaccine provides protection and cross-reactivity against JN.1 and numerous JN.1 lineage viruses, including KP.2.3, KP.3, KP.3.1.1, and LB.1.
Novavax says its vaccine&nbsp;is the only protein-based option available in the U.S. for individuals aged 12 and older to prevent COVID-19.
Doses are on track to be available as early as the end of next week, the company said in an email to Reuters.
In August, Novavax lowered its 2024 revenue guidance to $700 million – $800 million, including revenue recognition of Sanofi Payment, compared to the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40260847/covid-19-vaccine-maker-novavax-trims-annual-outlook-as-q2-sales-take-a-hit" rel="noreferrer noopener">consensus of $936.38 million</a>.
Earlier, the company expected sales of $970 million – $1.17 billion in combined revenue and Sanofi agreement payment.
Price Action: NVAX stock is up 3.30% at $12.79&nbsp;at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/08/40659011/johnson-johnson-spin-off-kenvue-wins-lawsuit-over-pain-killer-tylenol-rapid-release-gelcaps" target="_blank" rel="noreferrer noopener">Johnson &amp; Johnson-Spin Off Kenvue Wins Lawsuit Over Pain Killer Tylenol &#8216;Rapid Release&#8217; Gelcaps</a>.</li>
</ul>
Photo via Shutterstock

FDA Approves Novavax's Updated COVID Vaccine Targeting Currently Circulating Variants

Novavax shares are trading higher after the company announced that the Novavax COVID-19 Vaccine, NVX-CoV2705, received Emergency Use Authorization from the FDA for active immunization to prevent COVID-19 in individuals aged 12 and older.

<ul>
<li>Novavax expects pre-filled syringes will be broadly available in thousands of locations across the U.S.</li>
<li>Novavax's vaccine is the only protein-based option available in the U.S. for use in individuals aged 12 and older to prevent COVID-19</li>
</ul>
GAITHERSBURG, Md., Aug. 30, 2024 /PRNewswire/ --&nbsp;Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>), a global company advancing protein-based vaccines with its Matrix-M&#x2122; adjuvant,&nbsp;today announced the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for active immunization to prevent COVID-19 in&nbsp;individuals aged 12 and older. Novavax's vaccine is included in the recommendations issued by the U.S. Centers for Disease Control and Prevention (CDC) on <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4244188-1&amp;h=3431911246&amp;u=https%3A%2F%2Fir.novavax.com%2Fpress-releases%2FU-S-ACIP-Recommends-Use-of-Authorized-and-Approved-2024-2025-COVID-19-Vaccines&amp;a=June+27%2C+2024">June 27, 2024</a>.
Pre-filled syringes of the vaccine will be available in thousands of locations, including retail and independent pharmacies and regional grocers, following the Center for Biologics Evaluation and Research release of vaccine batches.

Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized And Recommended For Use In The U.S.

Novavax Says FDA Authorizes Updated COVID-19 Vaccine To Better Protect Against Currently Circulating Variants

U.S. CDC Says For This Season Peak Hospitalizations For For Flu And Covid Combined Is Forecasted To Be Similar Or Slightly Improved Over Last Season; Covid Continues To Cause More Serious Disease Than Flu

U.S. FDA Official Says Can't Comment On Novavax Covid-19 Vaccine But Says The Agency Would Take "Rapid Action" Once They Receive Data

Novavax shares are trading lower after the FDA left the company out when providing updates on its emergency use authorization (EUA) approval for vaccines.

Thursday, the FDA granted emergency use authorization (EUA) for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a monovalent (single) component that corresponds to the Omicron variant KP.2 strain of SARS-CoV-2.
The approval comes for the updated vaccines from Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) and Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) / BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>).
The mRNA COVID-19 vaccines have been <a target="_blank" href="https://www.fda.gov/news-events/press-announcements/fda-approves-and-authorizes-updated-mrna-covid-19-vaccines-better-protect-against-currently" rel="noreferrer noopener">updated</a> with this formula to more closely target currently circulating variants and provide better protection against serious consequences of COVID-19, including hospitalization and death.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40348867/struggling-covid-19-vaccines-from-astrazeneca-biontechpfizer-moderna-cut-incidence-of-arterial-th" rel="noreferrer noopener">Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows</a>.
In early June, the FDA advised manufacturers of licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 formula) should be monovalent JN.1 vaccines.
Based on the further evolution of SARS-CoV-2 and a rise in cases of COVID-19, the agency subsequently determined and advised manufacturers that the preferred JN.1-lineage for the COVID-19 vaccines (2024-2025 formula) is the KP.2 strain, if feasible.
The updated mRNA COVID-19 vaccines include Comirnaty and Spikevax, both of which are approved for individuals 12 years of age and older, and the Moderna COVID-19 Vaccine and Pfizer-BioNTech COVID-19 Vaccine, both of which are authorized for emergency use for individuals six months through 11 years of age.
<ul>
<li>Unvaccinated individuals six months through 4 years of age are eligible to receive three doses of the Pfizer-BioNTech COVID-19 Vaccine or two doses of the updated Moderna COVID-19 Vaccine.</li>
<li>Individuals six months through 4 years of age who have previously been vaccinated against COVID-19 are eligible to receive one or two doses of Moderna or Pfizer-BioNTech COVID-19 vaccines.</li>
<li>Individuals 5 through 11 years of age, regardless of previous vaccination, are eligible to receive a single dose of the updated, authorized Moderna or Pfizer-BioNTech COVID-19 vaccines; if previously vaccinated, the dose is administered at least 2 months after the last dose of any COVID-19 vaccine.</li>
<li>Individuals 12 and older can receive a single dose of Comirnaty or Spikevax.</li>
<li>Additional doses are authorized for certain immunocompromised individuals ages 6 months through 11 years, as described in vaccine fact sheets.</li>
</ul>
The FDA assessed manufacturing and nonclinical data to support the change to include the 2024-2025 formula in the mRNA COVID-19 vaccines.
Moderna said the Spikevax 2024-2025 formula is expected to be available across the U.S. in the days immediately <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/ac40514130/moderna-receives-u-s-fda-approval-for-updated-covid-19-vaccine-targeting-kp-2-variant-of-sars-cov" rel="noreferrer noopener">following approval</a>.
Pfizer also said shipping will <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/b40514565/pfizer-and-biontech-receive-u-s-fda-approval-authorization-for-omicron-kp-2-adapted-covid-19-vacci" rel="noreferrer noopener">begin immediately</a>.
Novavax Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) COVID-19 vaccine was left out in today&#8217;s approval. Earlier, the company mentioned that it anticipates commercial delivery of the protein-based vaccine in the U.S. in September, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40260847/covid-19-vaccine-maker-novavax-trims-annual-outlook-as-q2-sales-take-a-hit" rel="noreferrer noopener">pending authorization</a>.
Price Action: PFE stock is down 1.18% at $28.69, BNTX stock is down 0.85% at $88.23, MRNA stock is down 5.08% at $82.25, and NVAX stock is down 5.72% at $12.20 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/emerging-markets/24/08/40514588/indias-disney-reliance-merger-draws-antitrust-concerns-as-cricket-rights-remain-sticking" target="_blank" rel="noreferrer noopener">India&#8217;s Disney-Reliance Merger Draws Antitrust Concerns As Cricket Rights Remain Sticking Point</a>.</li>
</ul>
Photo via <a href="https://commons.wikimedia.org/wiki/File:Moderna_COVID-19_vaccine_%282021%29_F.jpg">Wikimedia Commons</a>

Large Cap

FDA Approves Updated COVID Vaccines From Pfizer And Moderna, But Leaves Out Novavax's Shot

Novavax Continues To Work With The U.S. FDA On Authorization Of 2024-2025 Formula Covid-19 Vaccine; Expect To Have Authorization For 2024-2025 Formula Covid-19 Vaccine In Time For Peak Vaccination Season

Investors will increasingly focus on upcoming economic data to gauge soft landing odds that have helped drive stock performance in 2024. Given an evolving macroeconomic landscape, it could be wise to invest in under-the-radar socks Workday (WDAY), CrowdStrike (CRWD), and Novavax (NVAX), which could be tomorrow's blue chips. Read more... In the evolving market landscape, savvy investors always look for the next big thing—those hidden gems that could transform into tomorrow's blue-chip giants. While household names like Apple and Amazon dominate headlines, many promising companies remain under the radar, quietly laying the groundwork for massive future growth.
Hence, let's look at lesser-known, fundamentally sound stocks, Workday, Inc. (<a href="https://stocknews.com/stock/WDAY/">WDAY</a>), CrowdStrike Holdings, Inc. (<a href="https://stocknews.com/stock/CRWD/">CRWD</a>), and Novavax, Inc. (<a href="https://stocknews.com/stock/NVAX/">NVAX</a>), which hold the potential to deliver substantial returns for those who spot them early and could be tomorrow's blue chips.
The economy rose faster than expected during the second quarter, with consumer spending, business investment, and inventories adding up to the Gross Domestic Product (GDP) growth. GDP increased at a <a href="https://www.reuters.com/markets/us/us-economic-growth-regains-steam-second-quarter-inflation-slows-2024-07-25/">2.8% annualized rate</a> last quarter, which was double the 1.4% growth in the first quarter. Economists polled by Reuters estimated GDP rising at a 2% rate.
Moreover, the Federal Reserve Chair Jerome Powell recently <a href="https://www.cnbc.com/2024/08/23/fed-chair-powell-indicates-interest-rate-cuts-ahead-the-time-has-come-for-policy-to-adjust.html">indicated interest rate cuts</a> ahead, though he didn't provide exact indications on timing or extent. Investors are focusing on economic data to gauge a soft landing that has helped drive stocks so far this year.
Stocks witnessed gains on Friday after Powell's comments, with the Dow Jones surging 1.14%, while the <a href="https://www.cnbc.com/2024/08/22/stock-market-today-live-updates.html">Nasdaq Composite rose 1.47%</a> and the S&amp;P 500 gained 1.15%.
Amid an improving macroeconomic backdrop, investors could consider buying under-the-radar stocks such as WDAY, CRWD, and NVAX, which could be future blue-chip powerhouses.
Let's discuss the fundamentals of the featured stocks in detail:
Workday, Inc. (<a href="https://stocknews.com/stock/WDAY/">WDAY</a>)
WDAY provides enterprise cloud applications that help its global customers plan, execute, analyze, and extend to diverse applications and environments to manage their business and operations.
On August 22, WDAY and Equifax Inc. (<a href="https://stocknews.com/stock/EFX/">EFX</a>), a global data, analytics, and technology company, announced a strategic partnership to help modernize the employment and income verification process for Workday customers' employees.
Matthew Brandt, senior vice president of global partners at Workday, said, "This partnership improves the employee experience by simplifying and speeding up the process by which they secure loans and government benefits, which frees up HR teams to focus on more meaningful work such as employee performance and wellbeing."
On August 20, WDAY announced the global release of Workday Payroll powered by Strada. The new AI-driven global HR and payroll solution offers organizations a unified view of their finance, HR, and payroll data, enhancing data accuracy, supporting compliance, and informing strategic initiatives that drive business growth and success.
For the second quarter that ended July 31, 2024, WDAY's revenue increased 16.7% year-over-year to $2.09 billion. Its non-GAAP <a href="https://www.investopedia.com/terms/o/operatingincome.asp#:~:text=Operating%20income%20is%20an%20accounting,of%20goods%20sold%20(COGS).">operating income</a> grew 23% from the year-ago value to $518 million. Its non-GAAP net income per share rose 22.4% from the prior year's period to $1.75. Its free cash flows were $516 million, up 43.3% year-over-year.
Analysts expect WDAY's revenue and EPS for the third quarter (ending October 2024) to increase 14.1% and 14.1% year-over-year to $2.13 billion and $1.75, respectively.  Moreover, the company surpassed the consensus revenue and EPS estimates in all four trailing quarters.
Shares of WDAY have surged 13.4% over the past month to close the last trading session at $259.95.
WDAY's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect this promising outlook. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
WDAY has an A grade for Growth and a B for Sentiment and Quality. Within the <a href="https://stocknews.com/category/software-application/">Software – Application</a> industry, it is ranked #22 out of 128 stocks. To see the additional ratings of WDAY for Value, Momentum, and Stability, <a href="https://stocknews.com/stock/WDAY/">click here</a>.
CrowdStrike Holdings, Inc. (<a href="https://stocknews.com/stock/CRWD/">CRWD</a>)
CRWD offers cybersecurity solutions globally. Its unified platform offers cloud-delivered protection of endpoints, cloud workloads, identity, and data. It provides corporate endpoint and cloud workload security, security and vulnerability management, IT operations management, data protection, security orchestration, and AI-powered workflow automation.
On June 26, CRWD announced that it exceeded $1 billion in total sales over the lifetime of its partnership with CDW Corporation (<a href="https://stocknews.com/stock/CDW/">CDW</a>), a prominent multi-brand provider of IT solutions. CrowdStrike and CDW jointly lead cybersecurity transformation for thousands of organizations globally through the AI-native <a href="https://www.crowdstrike.com/platform/">CrowdStrike Falcon&#xAE; platform</a>.
On June 18, CRWD partnered with Hewlett Packed Enterprise (<a href="https://stocknews.com/stock/HPE/">HPE</a>) to <a href="https://ir.crowdstrike.com/news-releases/news-release-details/crowdstrike-collaborates-hewlett-packard-enterprise-secure-end">secure end-to-end AI innovation</a>, including large language models (LLMs), accelerated by NVIDIA Corporation (<a href="https://stocknews.com/stock/NVDA/">NVDA</a>). Integrating the Falcon platform with HPE GreenLake cloud and OpsRamp AIOps unifies security and IT teams in monitoring accelerated AI workload IT alerts and adversary activity.
During the first quarter that ended April 30, 2024, CRWD's total revenue increased 33% year-over-year to $921.04 million. Its gross profit rose 33% from the year-ago value to $696.03 million. Its non-GAAP income from operations grew 71.5% year-over-year to $198.74 million.
Further, non-GAAP net income attributable to CrowdStrike came in at $231.67 million and $0.93 per share, up 69.9% and 63.2% from the prior year's quarter, respectively. Its free cash flow rose 41.8% year-over-year to $322.46 million.
Analysts expect CRWD's revenue for the second quarter (ended July 2024) to increase 31% year-over-year to $958.36 million. The consensus EPS estimate of $0.97 for the current quarter reflects a 30.5% year-over-year improvement. Moreover, the company has topped consensus revenue and EPS estimates in each of the trailing four quarters.
CRWD's stock has gained 6.4% year-to-date to close the last trading session at $271.54.
CRWD's sound fundamentals are reflected in its POWR Ratings. The stock has an A grade for Growth and a B for Quality. Within the B-rated <a href="https://stocknews.com/category/software-security/">Software – Security</a> industry, CRWD is ranked #18 out of 23 stocks.
<a href="https://stocknews.com/stock/CRWD/">Click here</a> to access additional ratings of CRWD (Value, Stability, Sentiment, and Momentum).
Novavax, Inc. (<a href="https://stocknews.com/stock/NVAX/">NVAX</a>)
NVAX is a biotechnology company that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases.
On July 2, NVAX submitted a request for authorization to Health Canada for its 2024-2025 Formula COVID-19 vaccine (NVX-CoV2705) for individuals aged 12 and older.
This filing aligns with the guidance from the National Advisory Committee on Immunization (NACI) to use the latest selected strain and the guidance from the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and the World Health Organization (WHO).
NVAX reported total revenue of $415.48 million in the second quarter that ended June 30, 2024. Its income from operations grew 190.3% from the prior year's quarter to $161 million. Its net income was $162.38 million, or $0.99 per share, up 179.9% and 70.7% year-over-year, respectively.
Furthermore, as of June 30, 2024, the company's cash and cash equivalents stood at $680.16 million, compared to $568.51 million as of December 31, 2023.
NVAX's stock has soared 126.7% over the past six months and 33.1% over the past year to close the last trading session at $11.99.
NVAX's sound fundamentals are reflected in its POWR Ratings. The stock has a B grade for Value and Growth. It is ranked #56 among 339 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry.
<a href="https://stocknews.com/stock/NVAX/">Click here</a> to access NVAX's ratings for Momentum, Stability, Quality, and Sentiment.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
WDAY shares rose $0.05 (+0.02%) in premarket trading Monday. Year-to-date, WDAY has declined -5.82%, versus a 19.19% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Mangeet Kaur Bouns</h2> <img src='https:/wp-content/uploads/2022/01/Mangeet-Kaur-Bouns_Image-4.jpg' style="float:left; padding:5px;width:125px;">Mangeet's keen interest in the stock market led her to become an investment researcher and financial journalist. Using her fundamental approach to analyzing stocks, Mangeet's looks to help retail investors understand the underlying factors before making investment decisions.<a href="https://stocknews.com/authors/?author=mangeet-kaurbouns">More...</a>The post <a href=https://stocknews.com/news/wday-nvda-efx-crwd-hpe-nvax-3-under-the-radar-stocks-that-could-be-tomorrows-blue-chips/>3 Under-the-Radar Stocks That Could Be Tomorrow's Blue Chips</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Under-the-Radar Stocks That Could Be Tomorrow's Blue Chips

Moderna's Vaccine Progress Undermined By RSV Market Contraction (Rating Downgrade)

Novavax gains on FDA emergency nod for updated COVID shot

Novavax's Future Hinges On Sanofi Deal And Upcoming Milestones

Novavax, Inc. (NVAX) H.C. Wainwright 26th Annual Global Investment Conference (Transcript)

Novavax, Inc. (NVAX) Baird 2024 Global Healthcare Conference (Transcript)

Novavax COVID-19 vaccines now available

Moderna's Move Shows Lack Of Confidence, Shrinks Pipeline

CRWD

CVAC

GLAXF

NVDA

SNYNF

WDAY

Press Releases

GameStop Raises $2.14 Billion, Meme Stocks Buzz Fuels Gains Watch: GME, PRSO, DYAI, VTAK, AMC

Novavax Submits Application to U.S. FDA for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine

Novavax Submits Application to European Medicines Agency for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine

Novavax Submits Application to Health Canada for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine

Novavax to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Operational Highlights on August 8, 2024

Earnings

Novavax Reports Second Quarter 2024 Financial Results and Operational Highlights

Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.

New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth

Novavax to Participate in Upcoming September Conferences

Novavax 2024-2025 Formula COVID-19 Vaccine Available at Major Pharmacies Across the U.S.

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Novavax

Novavax (NVAX) Forecast

Novavax (NASDAQ:NVAX) Stock, Quote.Headers.trade-ideas